Sandoz and Biocon strike global biosimilars alliance

Executive Summary

Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.